. 2017 Mar 5;23:1146–1155. doi: 10.12659/MSM.899646

Table 3.

Dose-dependent assay for anticancer evaluation.

Compound No.	N^a	LogGI₅₀			Log TGI			Log LC₅₀
Compound No.	N^a	N1^b	Range	MG_MID	N2^b	Range	MG_MID	N3^b	Range	MG_MID
BT1	3	3	−4.64 to −6.49	−5.07	56	−4.0 to −4.83	−4.4	19	−4.0 to −4.36	−4.06
BT4	3	3	−4.64 to −6.52	−5.33	37	−4.0 to 5.08	−4.36	09	−4.0 to −4.28	−4.02
BT8	3	3	−4.0 to −4.84	−4.45	08	−4.0 to −4.24	−4.02	00	−4.0 to −4.02	−4.0
BT17	3	3	−4.42 to −5.02	−4.71	25	−4.0 to −4.32	−4.07	03	−4.0 to −4.08	−4.0
BT18	3	3	−3.92 to −6.93	−4.90	49	−3.92 to −6.01	−4.07	49	−3.92 to −4.75	−4.29

N – no. of human cancer cell lines tested at the II^nd stage assay;

N1, N2, N3 – no. of sensitive cell lines, against which the compound possessed considerable growth inhibition as per the standard parameter (logGI₅₀, logTGI, and log LC50 ≥4.00) (GI₅₀ (50% of net cell growth inhibition at molar concentration of the compound.) TGI (Total inhibition at molar concentration of the compound) and LC₅₀ (50% of net cell death at molar concentration of the compound).